EVGN Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.889

Open

0.889

VWAP

0.85

Vol

95.53K

Mkt Cap

7.38M

Low

0.819

Amount

81.36K

EV/EBITDA(TTM)

--

Total Shares

8.72M

EV

8.67M

EV/OCF(TTM)

--

P/S(TTM)

1.73

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Show More

Events Timeline

(ET)

2026-03-05

07:10:00

Evogene Reports Q4 Revenue of $314M

2026-02-17 (ET)

2026-02-17

08:10:00

Evogene Partners with QUT to Develop Novel Cancer Drugs

2026-02-11 (ET)

2026-02-11

08:10:00

Evogene Collaborates with Systasy to Develop New Therapies

2026-02-10 (ET)

2026-02-10

08:20:00

Evogene Expands Collaboration with Google Cloud

2026-02-05 (ET)

2026-02-05

06:00:00

Evogene and Shanghai Lishan Biopharmaceuticals Sign Exclusive Licensing Agreement for BMC128

2026-02-04 (ET)

2026-02-04

08:10:00

Evogene and Shanghai Lishan Biopharmaceuticals Sign Exclusive Licensing Agreement for BMC128

2026-01-07 (ET)

2026-01-07

07:20:00

Evogene Partners with Unravel Biosciences to Develop Neurological Disease Therapy

2025-12-30 (ET)

2025-12-30

07:10:00

Evogene Appoints Dr. Olga Nissan as VP of Business Development

2025-11-11 (ET)

2025-11-11

07:05:33

Evogene's Casterra and Fantini Reveal Strategic Partnership

News

PRnewswire

03-09PRnewswire

Evogene to Present at BIO-Europe Spring 2026 Conference

Globenewswire

03-06Globenewswire

On-Demand Access to Clean Energy Virtual Investor Conference Presentations

seekingalpha

03-05seekingalpha

Evogene Ltd. Q4 2025 Earnings Call Insights

PRnewswire

03-05PRnewswire

Evogene Reports 2025 Financial Results, Focuses on Core Technology

seekingalpha

03-05seekingalpha

Evogene Reports Q4 Earnings with Significant Revenue Decline

seekingalpha

03-04seekingalpha

Evogene Set to Announce Q4 Earnings Results

1 Analyst Rating

Wall Street analysts forecast EVGN stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.50

Averages

2.50

High

2.50

Current: 0.000

Low

2.50

Averages

2.50

High

2.50

Alliance Global

Buy

downgrade

AI Analysis

2026-03-13

Reason

Alliance Global

Price Target

AI Analysis

2026-03-13

downgrade

Buy

Reason

Alliance Global lowered the firm's price target on Evogene to $1.75 from $2.50 and keeps a Buy rating on the shares. Evogene reported Q4 earnings that were within the range of expectations, the analyst tells investors in a research note. The firm said the main points include: the company's focus is on the ChemPass AI discovery engine; the company has already reached four collaborations and more are expected; the firm expects molecules to enter preclinical testing in 1H27, and; the cash balance appears to extend into 2H27.

Alliance Global Partners

Scott Henry

Buy

downgrade

$6

2025-06-06

Reason

Alliance Global Partners

Scott Henry

Price Target

$6

2025-06-06

downgrade

Buy

Reason

Alliance Global Partners analyst Scott Henry lowered the firm's price target on Evogene to $3.50 from $6 and keeps a Buy rating on the shares, citing lower forecasts and potentially higher equity dilution after the company reported Q1 earnings that featured a revenue shortfall offset by cost cuts. The Lavie Bio sale should fortify the balance sheet, although at a lower price than expected, and Casterra castor seed revenue continues to trail the firm's forecasts, the analyst noted.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EVGN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Evogene Ltd (EVGN.O) is -0.97, compared to its 5-year average forward P/E of -1.72. For a more detailed relative valuation and DCF analysis to assess Evogene Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-1.72

Current PE

-0.97

Overvalued PE

-0.35

Undervalued PE

-3.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.66

Current EV/EBITDA

-1.57

Overvalued EV/EBITDA

0.08

Undervalued EV/EBITDA

-1.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

26.56

Current PS

3.53

Overvalued PS

81.47

Undervalued PS

-28.35

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

stocks under $2 for day trade today

Intellectia · 158 candidates

Price: <= $2.00Volume: >= 500,000Price Change Pct: $-5.00 - $20.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Phio Pharmaceuticals Corp

12.06M

Plug Power Inc

2.84B

NUBURU Inc

56.42M

Tian Ruixiang Holdings Ltd

10.04M

Jet.AI Inc

5.61M

Bit Digital Inc

563.19M

stocks between $1.00 and $1.10

Intellectia · 54 candidates

Price: $1.00 - $1.10

Ticker

Name

Market Cap$

Adagio Medical Holdings Inc

22.87M

Heidmar Maritime Holdings Corp

61.90M

CCSC Technology International Holdings Ltd

4.15M

Auddia Inc

3.35M

Estrella Immunopharma Inc

42.45M

CytoMed Therapeutics Ltd

11.15M

Whales Holding EVGN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Evogene Ltd (EVGN) stock price today?

The current price of EVGN is 0.846 USD — it has decreased -0.12

What is Evogene Ltd (EVGN)'s business?

Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

What is the price predicton of EVGN Stock?

Wall Street analysts forecast EVGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVGN is2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Evogene Ltd (EVGN)'s revenue for the last quarter?

Evogene Ltd revenue for the last quarter amounts to 314.00K USD, decreased -80.51

What is Evogene Ltd (EVGN)'s earnings per share (EPS) for the last quarter?

Evogene Ltd. EPS for the last quarter amounts to -0.61 USD, decreased -1116.67

How many employees does Evogene Ltd (EVGN). have?

Evogene Ltd (EVGN) has 117 emplpoyees as of March 22 2026.

What is Evogene Ltd (EVGN) market cap?

Today EVGN has the market capitalization of 7.38M USD.